Hypothesis

We propose that declining NAD+ levels in endothelial cells reduce SIRT1 activity, which impairs the regeneration of tetrahydrobiopterin (BH4) and promotes eNOS uncoupling long before senescent cell accumulation drives arterial stiffness. Restoring NAD+ preserves BH4, keeps eNOS coupled, and prevents the oxidative‑stiffness feedback loop described by et al. et al.

Mechanistic Rationale

• NAD+ is a required cofactor for SIRT1 deacetylase activity, which modulates GTP cyclohydrolase I (GCH1), the rate‑limiting enzyme in BH4 synthesis.SIRT1 and GCH1 regulation
• When NAD+ falls, SIRT1‑mediated deacetylation of GCH1 diminishes, lowering BH4 pools and shifting eNOS toward superoxide production.NAD+ decline and eNOS uncoupling
• Superoxide reacts with NO to form peroxynitrite, which further oxidizes BH4, creating a vicious cycle that precedes measurable increases in carotid‑femoral pulse wave velocity (cfPWV).Oxidative feedback loop
• In young women, biological age derived from circulating biomarkers correlates more strongly with cfPWV than chronological age, suggesting that metabolic disturbances such as NAD+ decline may be an early driver of vascular aging.Biological age and PWV

Testable Predictions

1. Endothelial NAD+ concentration will be inversely correlated with plasma ADMA and positively correlated with BH4/BH2 ratios in individuals aged 20‑35 years, independent of traditional risk factors.
2. Pharmacologic elevation of NAD+ (e.g., with nicotinamide riboside) will increase SIRT1 activity, restore BH4 levels, decrease eNOS‑derived superoxide, and lower cfPWV after 12 weeks, whereas senolytic treatment alone will not affect these early markers.
3. Combining NAD+ augmentation with intermittent senolytic dosing will produce additive reductions in cfPWV and improve endothelial‑dependent vasodilation more than either monotherapy.

Experimental Design

• Cohort: Recruit 120 healthy volunteers aged 20‑35, stratified by sex and baseline cfPWV.
• Interventions: (a) placebo, (b) NAD+ precursor (NR 500 mg bid), (c) senolytic (dasatinib + quercetin weekly), (d) NR + senolytic.
• Outcomes measured at baseline, 6 weeks, 12 weeks:
  • Plasma NAD+, SIRT1 activity (fluorometric assay), GCH1 acetylation (Western blot).
  • BH4/BH2 ratio (HPLC).
  • Plasma ADMA, nitrotyrosine (peroxynitrite marker).
  • Endothelial function: flow‑mediated dilation (FMD).
  • Arterial stiffness: cfPWV (applanation tonometry).
• Analysis: Mixed‑effects models adjusting for baseline values, sex, and BMI; test interaction between NAD+ and senolytic arms.

Potential Implications

If NAD+ restoration prevents early eNOS uncoupling, it could shift the therapeutic window for vascular aging upstream of senescence, offering a preventive strategy that attenuates arterial stiffness before structural remodeling becomes irreversible. This hypothesis directly addresses the translational gap noted by et al.—the lack of causal evidence that reducing PWV prevents hard outcomes—by targeting a mechanistic precursor that is modifiable and measurable in early adulthood.